https://ddn.pluspedia.org/w/index.php?action=history&feed=atom&title=Phosphatbinder 2026-11-05T05:38:17Z Versionsgeschichte dieser Seite in PlusPedia MediaWiki 1.43.3 https://ddn.pluspedia.org/w/index.php?title=Phosphatbinder&diff=43418&oldid=prev 2010-04-14T21:41:19Z

<p>Die Seite wurde neu angelegt: „<a href="/wiki/Datei:Pptpdtjpg1.png" title="Datei:Pptpdtjpg1.png">miniatur|Entstehender Artikel</a> {| class=&quot;wikitable&quot; | | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Siehe auch&#039;&#039;&#039; | align=&quot;left&quot; width=&quot;800&quot; | |- | bgcolor=&quot;#d…“</p> <p><b>Neue Seite</b></p><div>[[Datei:pptpdtjpg1.png|miniatur|Entstehender Artikel]]<br /> {| class=&quot;wikitable&quot; |<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Siehe auch&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot; |<br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Freie Übersichtsartikel&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot; |<br /> &lt;ref name=&quot;PMID18045858&quot;&gt;Battleground: chronic kidney disorders mineral and bone disease--calcium obsession, vitamin d, and binder confusion. Clin J Am Soc Nephrol 3(1):168-73 (2008) PMID 18045858 &lt;/ref&gt;&lt;ref name=&quot;PMID16251245&quot;&gt;Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16 Suppl 2():S107-14 (2005) PMID 16251245 &lt;/ref&gt;&lt;ref name=&quot;PMID12939384&quot;&gt;New developments in hyperphosphatemia management. J Am Soc Nephrol 14(9 Suppl 4):S297-9 (2003) PMID 12939384 &lt;/ref&gt;&lt;ref name=&quot;PMID18449174&quot;&gt;Hyperphosphatemia of chronic kidney disease. Kidney Int 74(2):148-57 (2008) PMID 18449174 &lt;/ref&gt;&lt;ref name=&quot;PMID16766546&quot;&gt;Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrol Dial Transplant 21(8):2065-8 (2006) PMID 16766546 &lt;/ref&gt;&lt;ref name=&quot;PMID16332702&quot;&gt;Hyperphosphataemia and related mortality. Nephrol Dial Transplant 21(2):273-80 (2006) PMID 16332702 &lt;/ref&gt;&lt;ref name=&quot;PMID15126650&quot;&gt;Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 19 Suppl 1():i19-24 (2004) PMID 15126650 &lt;/ref&gt;&lt;ref name=&quot;PMID15126649&quot;&gt;Improving outcomes in hyperphosphataemia. Nephrol Dial Transplant 19 Suppl 1():i14-8 (2004) PMID 15126649 &lt;/ref&gt;&lt;ref name=&quot;PMID12105237&quot;&gt;Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant 17(7):1170-5 (2002) PMID 12105237 &lt;/ref&gt;&lt;ref name=&quot;PMID11981055&quot;&gt;Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17(5):723-31 (2002) PMID 11981055 &lt;/ref&gt;&lt;ref name=&quot;PMID11773454&quot;&gt;Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 17(1):14-7 (2002) PMID 11773454 &lt;/ref&gt;&lt;ref name=&quot;PMID11071956&quot;&gt;Managing phosphate retention: is a change necessary? Nephrol Dial Transplant 15(11):1738-42 (2000) PMID 11071956 &lt;/ref&gt;&lt;ref name=&quot;PMID10489212&quot;&gt;Hyperphosphataemia--a silent killer of patients with renal failure? Nephrol Dial Transplant 14(9):2085-7 (1999) PMID 10489212 &lt;/ref&gt;&lt;ref name=&quot;PMID9568822&quot;&gt;The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 13 Suppl 3():57-61 (1998) PMID 9568822 &lt;/ref&gt;&lt;ref name=&quot;PMID8671808&quot;&gt;Treatment of hyperparathyroidism--why is it crucial to control serum phosphate? Nephrol Dial Transplant 11(3):420-3 (1996) PMID 8671808 &lt;/ref&gt;<br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Wichtige Übersichtsartikel&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Medline Suchterm/ Synonyme&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#00dfdf&quot; | &#039;&#039;&#039;Was ist das&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Struktur&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Physiologie&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Knockout&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Transgen&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Mutation&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Polymorphismus&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Genexpression&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Inhibitoren&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Agonisten&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |}<br /> <br /> ----<br /> <br /> == Bibliographie ==<br /> &lt;references /&gt;<br /> <br /> <br /> {{LinkWP_Miniartikel|Txt=Phosphatbinder|Link=Phosphatbinder}}</div>

Ossip Groth